- Fundamental required for all siRNA therapeutics
- Chemistry required to introduce drug like properties
- Target IP related to siRNAs for specific disease targets.
The information below includes currently issued or granted patents, Alnylam’s patent estate includes additional pending patents in each category.
Fundamental Patents
Select the patent name or PDF link to view the granted or issued claim setsUnited States
- US 5,898,031: Crooke — PDF
- US 6,107,094: Crooke — PDF
- US 6,506,559: Fire and Mello — PDF
- US 7,056,704: Tuschl II — PDF
- US 7,078,196: Tuschl II — PDF
- EP 1144623: Kreutzer-Limmer — PDF
- Interlocutory Decision in Opposition Proceedings (German)—PDF (1.1 MB)
- Interlocutory Decision in Opposition Proceedings (English)—PDF (112 KB)
- Minutes of Opposition Oral Proceedings (German)—PDF (855 KB)
- Minutes of Opposition Oral Proceedings (English)—PDF (56 KB)
- EP 1214945: Kreutzer-Limmer — PDF
- EP 1407044 Tuschl II — PDF
- EP 1230375: Glover — PDF
- As a courtesy to interested parties, Alnylam has provided the original and translated documents below. However, Alnylam shall assume no responsibility for the accuracy or completeness of these translations. Where differences between the German original and the English translation are perceived, the German original shall prevail.
Chemistry
Select the patent name or PDF link to view the granted or issued claim setsUnited States United Kingdom